Publication
Barton ME, et al. Bepranemab in prodromal-to-mild Alzheimer's disease: a phase 2 randomised trial. Lancet Neurology, 2026
PMID 43008775
Phase 2 RCT of intravenous bepranemab versus placebo in 466 adults aged 50–80 with prodromal-to-mild Alzheimer's disease. The primary endpoint, CDR-SB change at week 80, was not met. Sponsor: UCB.
1 news item
News about this publicationScales
Identifiers
- PMID
- 43008775
- DOI
- 10.1016/S1474-4422(26)00357-1
Original sources
Details
- Journal
- Lancet Neurology
- Year
- 2026
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.